Recherche Images Maps Play YouTube Actualités Gmail Drive Plus »
Connexion
Les utilisateurs de lecteurs d'écran peuvent cliquer sur ce lien pour activer le mode d'accessibilité. Celui-ci propose les mêmes fonctionnalités principales, mais il est optimisé pour votre lecteur d'écran.

Brevets

  1. Recherche avancée dans les brevets
Numéro de publicationUSRE38341 E1
Type de publicationOctroi
Numéro de demandeUS 09/472,524
Date de publication9 déc. 2003
Date de dépôt27 déc. 1999
Date de priorité8 mai 1996
État de paiement des fraisPayé
Autre référence de publicationCA2253671A1, CA2253671C, EP0956091A1, EP0956091A4, US5676648, US5879323, USRE38000, WO1997041919A1
Numéro de publication09472524, 472524, US RE38341 E1, US RE38341E1, US-E1-RE38341, USRE38341 E1, USRE38341E1
InventeursJulian L. Henley
Cessionnaire d'origineBiophoretic Therapeutic Systems, Llc
Exporter la citationBiBTeX, EndNote, RefMan
Liens externes: USPTO, Cession USPTO, Espacenet
Method for electrokinetic delivery of medicaments
US RE38341 E1
Résumé
A portable iontophoresis apparatus for facilitating delivery of medication across the cutaneous membrane into adjacent underlying tissues and blood vessels. The apparatus employs a modular, detachable non-reusable medicament-containing applicator electrode which is adapted to attach to a base assembly. The apparatus is designed to be hand-held and includes a circumferential tactile electrode band on the base assembly which provides electrical connection between the skin of the user's hand and one pole of a bipolar power source housed within the base assembly. The opposing pole of the power source is connected to the applicator electrode. The user's body completes the electrical circuit between the applicator and tactile electrodes. A method for using the device for the treatment of Herpes simplex infection and related viral infections which produce similar cutaneous lesions is presented. The apparatus, when used in accordance with the method described herein, demonstrated >90% treatment efficacy in clinical trials.
Images(2)
Previous page
Next page
Revendications(51)
What I claim is:
1. A method for treating mucocutaneous Herpes Type I and Type II infections present mucocutaneous lesion comprising the iontophoretic transdermal delivery of a [2-hydroxyethoxy(methyl)]guanine into tissue overlying said lesion.
2. A method for treating Herpes conditions in accordance with claim 1 for clinical conditions suspected to be caused by Herpes Simplex virus infection.
3. A method for treating lesions associated with cold sores and genital herpes comprising the dispensation, application and transdermal self-application of an active antiviral agent contained within a hand-held iontophoretic device to said lesions wherein said antiviral agent is 5-iodo-2-deoxyuridine or derivatives thereof.
4. A method of treating Herpes Type I and Type II infection in an individual by self-administration of an anti-viral agent, the method comprising the steps of:
(a) providing a portable hand-held electrokinetic device having an applicator electrode in electrical communication with a self-contained electrical power source housed within the device, said applicator electrode including an electrokinetically transportable anti-viral agent comprising 9 -[ 2 -hydroxyethoxy(methyl)]guanine effective for treating Herpes Type I and Type II infection, a contact surface, and a substrate having a reservoir containing said anti-viral agent;
(b) rupturing the reservoir to supply the anti-viral agent to the substrate;
(c) while holding the device, manipulating the device to place the contact surface of the applicator electrode into overlying relation with an individual's infection site with the anti-viral agent in the substrate interposed between said applicator electrode and the infection site enabling electrical contact between the applicator electrode and the infection site;
(d) applying from said electrical power source a voltage gradient between the applicator electrode and the infection site to establish electrical contact therebetween by completing an electrical circuit with said power source through the individual's hand holding the device, the infection site, the anti-viral agent and the applicator electrode, whereby said anti-viral agent is electrokinetically motivated from the substrate into the infection site; and
(e) while holding the device in overlying relation with the infection site, providing the electrical contact between the applicator electrode and the infection site until a therapeutically effective dose of said anti-viral agent has been electrokinetically transported into said infection site.
5. The method of claim 4 including, after use, removing the applicator electrode from the device and replacing the used applicator electrode on the device with a replacement applicator electrode.
6. The method of claim 4, including preventing reuse of the applicator electrode after a one-time use thereof.
7. The method of claim 4 including indicating usage of the applicator electrode.
8. The method of claim 4 including providing a tactile electrode on said device for contact by the individual's hand holding the device, said tactile electrode being in electrical contact with said power source, the step of completing the electrical circuit including contacting the device with a portion of the individual's hand to provide electrical contact between the tactile electrode and the individual's hand holding the device.
9. A method according to claim 4 including providing a voltage multiplier within said device in electrical contact with said power source for stepping up the voltage supplied said applicator electrode.
10. A method according to claim 9 including providing a current driver within said device in electrical contact with said voltage multiplier and said applicator electrode for presenting a voltage output sufficient to maintain a defined current at said applicator electrode and incrementally increasing the level of the current at the start of the treatment to a predetermined controlled current level.
11. A method according to claim 4 including providing said hand-held device with a prepackaged unit dose of said anti-viral agent.
12. A method according to claim 4 wherein the method includes treating clinical conditions suspected to be caused by Herpes Simplex virus infection.
13. A method according to claim 4 including forming said rupturable reservoir of a material inert to said anti-viral agent.
14. A method of treatment by electrokinetic self-application of a medicament into a treatment site for an individual comprising the steps of:
(a) providing a portable hand-held electrokinetic device having an applicator electrode and a ground electrode in electrical communication with a self-contained electrical power source housed within the device, said applicator electrode including a prepackaged unit dose of an electrokinetically transportable medicament, a reservoir containing the medicament, a contact surface and a substrate;
(b) rupturing the reservoir to supply the medicament to the substrate;
(c) placing the contact surface of the applicator electrode into electrical contact with the individual's treatment site and placing the ground electrode into electrical contact with another site on the individual's body;
(d) causing electrical current to flow through said applicator electrode, the medicament in the substrate interposed between the applicator electrode and the treatment site, the treatment site, and the ground electrode by way of the individual's treatment site and said another site for electrokinetically motivating said medicament from the substrate into the individual's treatment site by the flow of electrical current from said self-contained power source; and
(e) maintaining said electrical current flow until a therapeutically effective dose of said medicament has been transported into the individual's treatment site.
15. A method according to claim 14 wherein said prepackaged unit dose of said medicament comprises 5-iodo- 2 -deoxyuridine.
16. A method according to claim 14 wherein said prepackaged unit dose of said medicament comprises 9-[ 2 -hydroxyethoxy(methyl)]guanine.
17. A method according to claim 14 including providing a tactile electrode on said device for contact by a portion of the individual's hand holding the device and in electrical contact with said power source, the step of completing the electrical circuit including grasping the device to provide electrical contact between the tactile electrode and the portion of the individual's hand holding the device.
18. A method according to claim 14, including, after use, removing the applicator electrode from the handpiece and replacing the used applicator electrode on the device with a replacement applicator electrode.
19. A method according to claim 14, including preventing reuse of the applicator electrode after a one-time use thereof.
20. A method according to claim 14 including maintaining an electrical current output level at the applicator electrode between 0.1 and 5 milliampere per square centimeter of said applicator electrode.
21. A method according to claim 14 including maintaining an electrical current output level at the applicator electrode between 0.1 and 1.2 milliampere per square centimeter of said applicator electrode.
22. A method according to claim 14 including incrementally increasing the level of current at the start of the treatment to a predetermined controlled current level.
23. A method according to claim 14 including incrementally increasing the level of current at the start of the treatment to a predetermined controlled current level and gradually terminating the electrical current to the electrode at the end of the treatment.
24. A method according to claim 14 wherein said medicament comprises an anesthetic.
25. A method according to claim 24 wherein said anesthetic comprises xylocaine.
26. A method according to claim 14 including applying steps (a)-(e) for treating clinical conditions suspected to be caused by Herpes Simplex virus infection.
27. A method of treatment by electrokinetic self-application of a medicament into a treatment site for an individual comprising the steps of:
(a) providing a portable hand-held electrokinetic device having an applicator electrode and a ground electrode in electrical communication with a self-contained electrical power source housed within the device, said applicator electrode including an electrokinetically transportable medicament and a contact surface;
(b) placing the contact surface of the applicator electrode into electrical contact with the individual's treatment site and placing the ground electrode into electrical contact with another site on the individual's body;
(c) causing electrical current to flow through said applicator electrode, the medicament interposed between the applicator electrode and the treatment site, the treatment site, and the ground electrode by way of the individual's treatment site and said another site for electrokinetically motivating said medicament into the individual's treatment site by the flow of electrical current from said self-contained power source;
(d) maintaining said electrical current flow until a therapeutically effective dose of said medicament has been transported into the individual's treatment site; and
(e) providing said applicator electrode with a substrate comprising a porous matrix and a rupturable reservoir formed of a material inert to said medicament and containing a unit dose of said medicament, and, after rupturing the reservoir, electrokinetically driving the medicament through the porous substrate into the individual's treatment site.
28. A method of treatment by electrokinetic self-application of a medicament into a treatment site for an individual comprising the steps of:
(a) providing a portable hand-held electrokinetic device having an applicator electrode and a ground electrode in electrical communication with a self-contained electrical power source housed within the device, said applicator electrode including an electrokinetically transportable medicament and a contact surface;
(b) placing the contact surface of the applicator electrode into electrical contact with the individual's treatment site and placing the ground electrode into electrical contact with another site on the individual's body;
(c) causing electrical current to flow through said applicator electrode, the medicament interposed between the applicator electrode and the treatment site, the treatment site, and the ground electrode by way of the individual's treatment site and said another site for electrokinetically motivating said medicament into the individual's treatment site by the flow of electrical current from said self-contained power source;
(d) maintaining said electrical current flow until a therapeutically effective dose of said medicament has been transported into the individual's treatment site; and
(e) preventing reuse of the applicator electrode after a one-time use thereof.
29. A method according to claim 28, wherein said medicament comprises 5-iodo- 2 -deoxyuridine or derivatives thereof.
30. A method according to claim 28 wherein said medicament comprises 9-[hydroxyethoxy(methyl)]guanine.
31. A method according to claim 28 wherein said medicament comprises an anesthetic.
32. A method according to claim 28 wherein said anesthetic comprises xylocaine.
33. A method according to claim 28 including providing a tactile electrode on said device for contact by a portion of the individual's hand holding the device and in electrical contact with said power source, the step of completing the electrical circuit including grasping the device to provide electrical contact between the tactile electrode and the portion of the individual's hand holding the device.
34. A method according to claim 28, including, after use, removing the applicator electrode from the handpiece and replacing the used applicator electrode on the device with a replacement applicator electrode.
35. A method according to claim 28 wherein said applicator electrode includes a substrate and a reservoir containing the medicament and including the step of rupturing the reservoir to supply medicament to the substrate and from the substrate through the contact surface into the individual's treatment site.
36. A method according to claim 35 wherein said substrate comprises a porous matrix and including forming said rupturable reservoir of a material inert to said medicament and, after rupturing the reservoir, electrokinetically driving the medicament through the porous substrate into the individual's treatment site.
37. A method according to claim 28 including maintaining an electrical current output level at the applicator electrode between 0.1 to 5 milliampere per square centimeter of said applicator electrode.
38. A method according to claim 28 including maintaining an electrical current output level at the applicator electrode between 0.1 and 1.2 milliampere per square centimeter of said applicator electrode.
39. A method according to claim 28 including incrementally increasing the level of current at the start of the treatment to a predetermined controlled current level.
40. A method according to claim 28 including incrementally increasing the level of current at the start of the treatment to a predetermined controlled current level and gradually terminating the electrical current to the electrode at the end of the treatment.
41. A method according to claim 28 for treating clinical conditions suspected to be caused by Herpes Simplex virus infection.
42. A method according to claim 28 including providing the applicator electrode with a prepackaged unit dose of medicament, and releasing the unit dose of medicament for electrokinetic transport through the contact surface of the applicator electrode into the treatment site.
43. A method of treatment by electrokinetic self-application of a medicament into a treatment site for an individual comprising the steps of:
(a) providing a portable hand-held electrokinetic device having an applicator electrode and a ground electrode in electrical communication with a self-contained electrical power source housed within the device;
(b) providing a voltage multiplier within said device in electrical contact with said power source and said applicator electrode for stepping up the voltage supplied said applicator electrode and providing a current driver within said device in electrical contact with said voltage multiplier and said applicator electrode for presenting a voltage output sufficient to maintain a defined current at said applicator electrode;
(c) locating the ground electrode on said device for contact by an individual's hand holding the device whereby the ground electrode serves as a tactile electrode;
(d) providing said applicator electrode with a prepackaged unit dose of an electrokinetically transportable medicament and a contact surface;
(e) while holding the device with the individual's hand in contact with the tactile electrode, placing the contact surface of the applicator electrode into electrical contact with the individual's treatment site;
(f) causing electrical current to flow through said applicator electrode, medicament interposed between the applicator electrode and the treatment site, the treatment site, and the tactile electrode by way of the individual's treatment site and the individual's hand holding the device in contact with the tactile electrode for electrokinetically motivating said medicament into the individual's treatment site by the flow of electrical current from said self-contained power source; and
(g) maintaining electrical current flow until the unit dose of medicament is at least partially depleted and a therapeutically effective dose of said medicament has been transported into the individual's treatment site, said applicator electrode including a substrate comprised of a porous matrix and a reservoir containing the prepackaged unit dose of medicament and inert to the medicament, including the step of rupturing the reservoir to supply medicament to the substrate and electrokinetically drive the medicament from the substrate through the contact surface into the individual's treatment site.
44. A method of treatment by electrokinetic self-application of a medicament into a treatment site for an individual, comprising the steps of:
(a) providing a portable electrokinetic device having a single one-time usage applicator electrode and a ground electrode in electrical communication with a self-contained power source housed within the device;
(b) providing a voltage multiplier within said device in electrical contact with said power source and said applicator electrode for stepping up the voltage supplied said applicator electrode and providing a current driver within said device in electrical contact with said voltage multiplier and said applicator electrode for presenting a voltage output sufficient to maintain a defined current at said applicator electrode;
(c) providing said applicator electrode with a prepackaged unit dose of an electrokinetically transportable medicament and a contact surface, said applicator electrode including a substrate having a reservoir containing said prepackaged unit dose of the medicament;
(d) rupturing the reservoir to supply the medicament to the substrate;
(e) locating the ground electrode on said device for contact by a portion of an individual's body whereby the ground electrode serves as a tactile electrode;
(f) placing the contact surface of the applicator electrode into electrical contact with the individual's treatment site;
(g) while maintaining the ground electrode in electrical contact with the individual's body portion and the contact surface of the applicator electrode in electrical contact with the individual's treatment site, causing electrical current to flow through said applicator electrode, the medicament interposed between the applicator electrode and the treatment site, the treatment site, and the tactile electrode by way of the individual's treatment site and the individual's body portion for electrokinetically motivating said medicament from the substrate into the individual's treatment site by the flow of electrical current from said self-contained power source; and
(h) maintaining electrical current flow until the unit dose of medicament is at least partially depleted and a therapeutically effective dose of said medicament has been transported into the individual's treatment site.
45. A method of treatment by electrokinetic self-application of a medicament into a treatment site for an individual, comprising the steps of:
(a) providing a portable electrokinetic device having applicator electrode and a ground electrode in electrical communication with a self-contained electrical power source housed within the device;
(b) providing a voltage multiplier within said device in electrical contact with said power source and said applicator electrode for stepping up the voltage supplied said applicator electrode and providing a current driver within said device in electrical contact with said voltage multiplier and said applicator electrode for presenting a voltage output sufficient to maintain a defined current at said applicator electrode;
(c) providing said applicator electrode with a prepackaged unit dose of an electrokinetically transportable medicament and a contact surface;
(d) locating the ground electrode on said device for contact by a portion of an individual's body whereby the ground electrode serves as a tactile electrode;
(e) placing the contact surface of the applicator electrode into electrical contact with the individual's treatment site;
(f) while maintaining the ground electrode in electrical contact with the individual's body portion and the contact surface of the applicator electrode in electrical contact with the individual's treatment site, causing electrical current to flow through said applicator electrode, the medicament interposed between the applicator electrode and the treatment site, the treatment site, and the tactile electrode by way of the individual's treatment site and the individual's body portion for electrokinetically motivating said medicament into the individual's treatment site by the flow of electrical current from said self-contained power source; and
(g) maintaining electrical current flow until the unit dose of medicament is at least partially depleted and a therapeutically effective dose of said medicament has been transported into the individual's treatment site, said substrate comprising a porous matrix and a rupturable reservoir of a material inert to said medicament and including the step of rupturing the reservoir to supply medicament to the substrate, and, after rupturing the reservoir, electrokinetically driving the medicament through the porous substrate into the individual's treatment site.
46. A method of treatment by electrokinetic self-application of a medicament into a treatment site for an individual, comprising the steps of:
(a) providing a portable electrokinetic device having an applicator electrode and a ground electrode in electrical communication with a self-contained electrical power source housed within the device;
(b) providing a voltage multiplier within said device in electrical contact with said power source and said applicator electrode for stepping up the voltage supplied said applicator electrode and providing a current driver within said device in electrical contact with said voltage multiplier and said applicator electrode for presenting a voltage output sufficient to maintain a defined current at said applicator electrode;
(c) providing said applicator electrode with a prepackaged unit dose of an electrokinetically transportable medicament and a contact surface;
(d) locating the ground electrode on said device for contact by a portion of an individual's body whereby the ground electrode serves as a tactile electrode;
(e) placing the contact surface of the applicator electrode into electrical contact with the individual's treatment site;
(f) while maintaining the ground electrode in electrical contact with the individual's body portion and the contact surface of the applicator electrode in electrical contact with the individual's treatment site, causing electrical current to flow through said applicator electrode, the medicament interposed between the applicator electrode and the treatment site, the treatment site, and the tactile electrode by way of the individual's treatment site and the individual's body portion for electrokinetically motivating said medicament into the individual's treatment site by the flow of electrical current from said self-contained power source;
(g) incrementally increasing the level of current at the start of the treatment to a predetermined controlled current level;
(h) maintaining electrical current flow at said controlled level until the unit dose of medicament is at least partially depleted and a therapeutically effective dose of said medicament has been transported into the individual's treatment site; and
(i) preventing reuse of the applicator electrode after a one-time use thereof.
47. A method according to claim 46 including releasing the prepackaged unit dose of medicament for electrokinetic transport through the contact surface of the applicator electrode into the treatment site.
48. A method of treatment by electrokinetic self-application of a medicament into a treatment site for an individual, comprising the steps of:
(a) providing a portable electrokinetic device having an applicator electrode and a ground electrode in electrical communication with a self-contained electrical power source housed within the device;
(b) providing a voltage multiplier within said device in electrical contact with said power source and said applicator electrode for stepping up the voltage supplied said applicator electrode and providing a current driver within said device in electrical contact with said voltage multiplier and said applicator electrode for presenting a voltage output sufficient to maintain a defined current at said applicator electrode;
(c) providing said applicator electrode with a prepackaged unit dose of an electrokinetically transportable medicament and a contact surface;
(d) locating the ground electrode on said device for contact by a portion of an individual's body whereby the ground electrode serves as a tactile electrode;
(e) placing the contact surface of the applicator into electrical contact with the individual's treatment site;
(f) while maintaining the ground electrode in electrical contact with the individual's body portion and the contact surface of the applicator electrode in electrical contact with the individual's treatment site, causing electrical current to flow through said applicator electrode, the medicament interposed between the applicator electrode and the treatment site, the treatment site, and the tactile electrode by way of the individual's treatment site and the individual's body portion for electrokinetically motivating said medicament into the individual's treatment site by the flow of electrical current from said self-contained power source;
(g) incrementally increasing the level of current at the start of the treatment to a predetermined controlled current level;
(h) maintaining electrical current flow at said controlled level until the unit dose of medicament is at least partially depleted and a therapeutically effective dose of said medicament has been transported into the individual's treatment site; and
(i) gradually terminating the electrical current to the electrode at the end of the treatment.
49. A method according to claim 48 including preventing reuse of the applicator electrode after a one-time use thereof.
50. A method according to claim 48 including releasing the prepackaged unit dose of medicament for electrokinetic transport through the contact surface of the applicator electrode into the treatment site.
51. A method of treating Herpes Type I and Type II infection in an individual by self-administration of an anti-viral agent, the method comprising the steps of:
(a) providing a portable hand-held electrokinetic device having an applicator electrode in electrical communication with a self-contained electrical power source housed within the device, said applicator electrode including a contact surface and a reservoir containing a unit dose of an electrokinetically transportable anti-viral agent comprising 9 -[ 2 -hydroxyethoxy(methyl)]guanine effective for treating Herpes Type I and Type II infection;
(b) releasing the unit dose of the anti-viral agent from the reservoir for electrokinetic transport through the contact surface of the applicator electrode into an individual's infection site;
(c) while holding the device, manipulating the device to place the contact surface of the applicator electrode into overlying relation with the individual's infection site to enable electrical contact between the applicator electrode and the infection site;
(d) applying from said electrical power source a voltage gradient between the applicator electrode and the infection site to establish electrical contact therebetween by completing an electrical circuit with said power source through the individual's hand holding the device, the infection site, the anti-viral agent and the applicator electrode, whereby said anti-viral agent is electrokinetically motivated into the infection site;
(e) incrementally increasing the level of current at the start of the treatment to a predetermined controlled current level;
(f) while holding the device in overlying relation with the infection site, providing the electrical contact between the applicator electrode and the infection site until a therapeutically effective dose of said anti-viral agent has been electrokinetically transported into said infection site; and
(g) preventing reuse of the applicator electrode after a one-time use thereof.
Description
REFERENCE TO RELATED APPLICATIONS

This application is a divisional of allowed U.S. patent application Ser. No. 08/646,853 filed May 8, 1996, now U.S. Pat. No. 5,676,648, issued Oct. 14, 1997.

BACKGROUND OF THE INVENTION

1. Field of the Invention

This invention relates generally to the transdermal electrokinetic mass transfer of medication into a diseased tissue, and, more specifically, to a portable apparatus for the iontophoretic delivery of medication across the skin and incorporation of the medication into diseased tissues and blood vessels adjacent to the delivery site. The apparatus provides a new method for treating and managing diseases presenting cutaneous lesions.

2. Prior Art

Iontophoresis has been employed for several centuries as a means for applying medication locally through a patient's skin and for delivering medicaments to the eyes and ears. The application of an electric field to the skin is known to greatly enhance the skin's permeability to various ionic agents. The use of iontophoretic transdermal delivery techniques has obviated the need for hypodermic injection for many medicaments, thereby eliminating the concomitant problems of trauma, pain and risk of infection to the patient.

Iontophoresis involves the application of an electromotive force to drive or repel oppositely charged ions through the dermal layers into a target tissue. Particularly suitable target tissue include tissues adjacent to the delivery site for localized treatment or tissues remote therefrom in which case the medicament enters into the circulatory system and is transported to a tissue by the blood. Positively charged ions are driven into the skin at an anode while negatively charged ions are driven into the skin at a cathode. Studies have shown increased skin penetration of drugs at anodic or cathodic electrodes regardless of the predominant molecular ionic charge on the drug. This effect is mediated by polarization and osmotic effects.

Regardless of the charge of the medicament to be administered, a iontophoretic delivery device employs two electrodes (an anode and a cathode) in conjunction with the patient's skin to form a closed circuit between one of the electrodes (referred to herein alternatively as a “working” or “application” or “applicator” electrode) which is positioned at the delivered site of drug delivery and a passive or “grounding” electrode affixed to a second site on the skin to enhance the rate of penetration of the medicament into the skin adjacent to the applicator electrode.

Recent interest in the use of iontophoresis for delivering drugs through a patient's skin to a desired treatment site has stimulated a redesign of many of such drugs with concomitant increased efficacy of the drugs when delivered transdermally. As iontophoretic delivery of medicaments become more widely used, the opportunity for a consumer/patient to iontophoretically administer a transdermal dosage of medicaments simply and safely at non-medical or non-professional facilities would be desirable and practical. Similarly, when a consumer/patient travels, it would be desirable to have a personal, easily transportable apparatus available which is operable for the iontophoretic transdermal delivery of a medication packaged in a single dosage applicator. The present invention provides a portable iontophoretic medicament delivery apparatus and a unit-dosage medicament-containing applicator electrode which is disposable and adapted for use with the apparatus for self-administering medicament.

SUMMARY OF THE INVENTION

The present invention discloses a portable iontophoretic transdermal or transmucoscal medicament delivery apparatus and a unit dosage medicament applicator electrode adapted for use with the apparatus for the self-administration of a unit dose of a medicament into the skin. The apparatus is particularly suited for the localized treatment of herpes infections. Recurrent herpetic infections (fever blisters or herpes labialis) are very common and usually involve the mucocutaneous juncture. The established treatment for recurrent herpetic lesions (oral or genital) has been primarily supportive; including local topical application of anesthesia. Severe cases have been treated with systemic Acyclovir® (Zovirax Burroughs-Wellcome). Some cases the condition is managed with prophylactic long-term dosing administration with a suitable anitviral agent at great expense. Systemic treatment of acute herpetic flare-ups may reduce the normal 10-12 day course of cutaneous symptoms into a 6-8 day episode. Topical treatment of lesions with Acyclovir® has not been as effective as in vitro studies would suggest. A compound which is not presently available to clinicians but has demonstrated significant anti herpetic activity is 5-iodo-2 deoxyuridine (IUDR). Both of those agents have shown limited clinical efficacy when applied topically to the herpetic lesion. It is the present inventor's contention that the limited efficacy of topical administration previously observed is, at least in part, due to the poor skin penetration of these medicaments when applied topically. The present invention provides improved transdermal delivery of these medicaments and demonstrates improved clinical results in the case of Herpes.

Oral Herpes (most commonly Herpes simplex I infection) as well as genital Herpes (usually Herpes Simplex II infection) afflict many people, cause discomfort, shame, and may contribute to more severe and costly illnesses such as cervical cancer, prostate cancer, and perinatal blindness from herpetic conjunctivitis. The present invention discloses a portable, user-friendly transdermal delivery device and a method for using the device with Acyclovir® [2-hydroxyethoxy(methyl)guanine (or similar antiviral agent) to greatly benefit these afflicted patients. The present inventor has constructed embodiments of this device and conducted human clinical trials which clearly demonstrate improved therapeutic efficacy using iontophoretically administered antiviral agents when compared to unassisted topical application of the agent.

It is an object of the present invention to provide an iontophoretic medicament delivery apparatus which is portable and operable for self-administration of medicament into the skin of a person.

It is another object of the present invention to provide an improved iontophoretic transdermal drub drug delivery apparatus having a medicament-containing application electrode which disperses a single dosage and is disposable and non-reusable.

It is a feature of the present invention that the iontophoretic medicament delivery apparatus is easily maneuverable and operable when hand-held.

It is another feature of the present invention that the iontophoretic medicament delivery apparatus is battery powered and conveniently transported by a person.

It is a further feature of the present invention that the iontophoretic medicament delivery apparatus employs a tactile electrode which is in electrical contact with the skin of a user's hand when the apparatus is held in the user's hand, obviating the need for a separate grounding electrode connector or wire:

It is still another feature of the present invention that the iontophoretic medicament delivery apparatus is adapted to be operable with a disposable medicament containing applicator electrode which applicator electrode includes an absorbent, inert, non-corrosive portion containing a therapeutic agent.

It is yet another feature of the present invention to provide an embodiment of an iontophoretic transdermal delivery device wherein the disposable iontophoretic medicament-containing applicator electrode is adapted for releasable attachment to use with a hand-held base assembly housing a grounding electrode.

It is yet another feature of the present invention that the disposable iontophoretic medicament applicator electrode include indicator means operable for enabling a user to determine when the medicament within the removable applicator electrode has been released in delivery and/or depleted.

It is yet another feature of the present invention that the circuitry employed in the disposable iontophoretic medicament applicator include current limiting means operable for limiting the electrical current flowing between the surface of the applicator and the skin to less than about one milliampere per square centimeters of application electrode skin-contacting surface.

It is another advantage of the present invention that the iontophoretic medicament delivery apparatus employs a disposable application electrode which conducts the electrical current to the tissue through the solution in which the medicament is dissolved.

It is still another advantage of the present invention that the improved disposable iontophoretic medicament applicator is inexpensive, safe to use and greatly increases the therapeutic efficacy of a medicament administered thereby.

The apparatus in accordance with the present invention provides a means for topically administering medicament directly and with high efficiency into a diseased tissue thereby providing a novel method for treating clinical conditions presenting mucocutaneous symptoms and particularly mucocutaneous Herpes Simplex viral eruptions and sequelle associated therewith.

The above objects, features and advantages of the invention are realized by the improved monopolar iontophoretic medicament applicator which is easily transportable. The applicator employs a detachable medicament containing application electrode. The objects, features and advantages of the invention will become apparent upon consideration of the following detailed disclosure of the invention, especially when it is taken in conjunction with the accompanying drawings wherein:

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a side elevational plan view of the iontophoretic medicament delivery apparatus showing the circumferential tactile ground electrode on the outer surface of the base housing and a disposable iontophoretic application electrode;

FIG. 2 is a side elevational view of the disposable non-reusable iontophoretic application electrode with a portion broken away to view the medicament dose packet;

DESCRIPTION OF THE PREFERRED EMBODIMENT

FIG. 1 shows, in side elevation, a preferred embodiment of the hand-held iontophoretic transdermal medicament delivery apparatus of the present invention. The apparatus, indicated generally by the numeral 10, has an elongate base assembly 11 the major portion of which is preferably formed of plastic and shaped to conform to and comfortably fit within a users hand. An applicator electrode module 12, containing a unit dose of medicament 23, is releasably attached to a applicator electrode receptacle 14 on the distal end of the base assembly 11. The application electrode 12 is preferably a “clip-on” type of electrode similar in configuration to an electrocardiogram electrode. In the drawing presented in FIGS. 1 and 2, electrically conductive elements such as wires and busses are presented as heavy lines. A wire 16 provides electrical connection between the applicator electrode receptacle 14 and wire 18 within the neck 15 of the base assembly 11. Connecting wire 18, in turn, provides electrical connection between the wire 16 and the current driver unit 19 housed within the base assembly 11. A conductive tactile electrode 20 forms a portion of the exterior skin-contacting surface of the base assembly 11 preferably circumferentially enclosing a portion of the base housing or it may be interrupted or discontinuous on the outer surface. The tactile electrode 20 is in electrical communication with the cathode 24C of battery 24 by means of a buss 17 and conductive urging spring 25 which secures the battery in position within the base assembly 11. For the self-administration of medicament a user must have skin contact with the tactile electrode 20 for the unit to operate. Current driver 19 underlies the cathodic (ground) tactile electrode 20 and is electrically connected via wire 21 to a voltage multiplier 22. The voltage multiplier 22 receives low voltage power from the anode 24a of the battery power source 24 and increases the available voltage for presentation to the application electrode 12. The battery 24, a self-contained electrical power source, is preferably a size AA or AAA. Battery 24 is held in place by an electrically conductive biasing spring 25 and ensures that electrical power is available at the application electrode 12 when the user grasps and holds the base housing 11 of the apparatus 10 thereby touching the cathodic tactile electrode 20. The application electrode 12 and the tactile electrode 20 thus form a closed circuit in series with the user's skin.

When current flows across the user's skin to from the application electrode in response to an applied voltage the current promotes and hastens the penetration of the medicament 23 contained in a reservoir 26 within the working electrode 12 into the skin. The polarity of the working electrode 12 is preferably unidirectional to promote the above described penetration without requiring a separate grounding electrode. The working application electrode 12 will be described in greater detail below.

The base assembly 11 of apparatus 10 serves as a housing to the aforesaid components as a handle. The portion of the base assembly 11, exclusive of the tactile electrode, is preferably made of a plastic such as polyethylene, acrylonitrile, butadiene, styrene or similar durable plastic. The battery portion 24 is connected to a voltage multiplier 22 which steps up the voltage supplied by the battery 24 and applies the stepped up voltage to the current driver 19. Current driver 19 presents a defined current and voltage output at the application electrode 12 the value of the current, which may be empirically determined being sufficient to drive the medicament through the porous, open-celled material 27 (FIG. 2) within the application electrode interposed between the skin contacting surface 13 and reservoir 26 containing the unit dose medicament and penetrate the patient's skin. The circuitry limits the maximum current available to the application electrode to preferably to less than about one milliampere per two square centimeters of the skin-contacting surface area 13 of the application electrode 12. However, depending upon working electrode's 12 skin-contacting surface 13 configuration, the current level can vary from about 0.1 to about 1.2 milliamps. Currents ranging between 0.1 ma to 5 ma have been used clinically by the present inventor, but the higher currents caused the user minor discomfort and, with chronic use over time, may produce untoward effects.

FIG. 2 shows a preferred embodiment of the iontophoretic medicament-containing application electrode 12. The application electrode 12 is preferably disposable and non-reusable and is suitable, for example, for transdermally delivering antiviral agents such as Acyclovir® for the treatment of cold sores or genital herpes. The size of the skin-contacting surface 13 of application electrode 12 may vary to accommodate specific clinical applications. The application electrode 12 is detachably housed within a recess within the receptacle 14 which recess presents an electrically conductive interior surface to complete the electrical flow path from the connecting wires 18 and 16 to a conductive element 29 within the application electrode. The electrical current from the current driver 19 is conducted through conductive inner surface of the application electrode receptacle 14 to the electrically conductive element 29 within the applicator electrode which element 29 is in electrical contact with the inner surface of the receptacle in contact therewith to drive the medicament 23 or treatment agent through the open-celled sponge-like like matrix material 27 and through the user's skin (not shown). The medicament or treatment agent 23 is contained within a rupturable polymer reservoir 26 until dispensed during treatment. A slight exertion of pressure or squeezing of the reservoir 26 against reservoir puncture means 28 releases the medicament or treatment agent into an open-celled sponge-like material 27 within the application electrode for iontophoretic delivery into the patient's skin. Medicament 23 release can occur at the time of application or upon peruse compression of the electrode 12. Application electrode 12 can be advantageously designed to include a stripping portion adapted so that upon removal of the application electrode 12 from the electrode receptacle 14 a protruding stripping portion (not shown) scrapingly strips the conductive coating from the conductive support arm 29 to prevent reuse of the disposable electrode 12. Application electrode 12 is intentionally packaged with a single dose packet or reservoir 26 of treatment agent or medicament 23. In addition to the medicament, the reservoir 26 can include a coloring agent, such as iodine, which turns dark blue upon contact with starch in the open-celled material to visibly indicate that the unit dose encapsulation has been used. Other suitable coloring agents can include pH indicators, wet saturation indicators or oxidizable pigments.

The open-celled sponge-like material 27, i.e., a substrate, surrounding reservoir 26 should be inert to the medicament or treatment agent being employed, as well as being non-corrosive and stable when in contact with the treatment agent. Suitable materials include plastic pads, such as polyethylene, paper or cotton, porous ceramics, open-celled porous polytetrafluoroethylene, polyurethane and other inert plastics, and open-celled silicone rubber, such as may be employed with vertically aligned medicament-containing tubes. A typical medicament that can be contained within the rupturable polymer reservoir 26 is xylocaine or similar topical anesthetic. The disposable electrode 12 possesses the advantages of preventing leaching or migration of the medicament from within the rupturable polymer reservoir, no attendant loss of efficacy, a long shelf life and little or no electrode corrosion. A suitable electrical control circuit for use in the iontophoretic medicament delivery apparatus 12 is shown in U.S. patent application, Ser. No. 07/579,799, filed Sep. 10, 1990, now U.S. Pat. No. 5,160,316 and hereby specifically incorporated by reference herein in pertinent part.

Experimental Clinical Trials

The inventor has conducted a clinical study using a prototype iontophoretic device in accordance with the present invention for the treatment of cold sores. The clinical response was promising. A second independent, qualified investigator, a board-certified Urologist, conducted a study using the present apparatus and method for treating male genital herpes lesions with encouraging results. Table 1 summarizes data (discussed below) supporting the claim to unexpected clinical benefits treating disease with this novel method. The method and medicament application device when used together for treating these common, embarrassing, and previously not easily-treatable ailments provide surprising advantages.

The embodiment of the device shown in FIG. 1 and described hereinabove is a improvement over the prototype used in the clinical study, which was a larger unit, not user friendly, which required physically connecting wires to the patient's body which created anxiety, and could not be used without attending personnel. Notwithstanding design, the apparatus used in the clinical study summarized in Table 1 employed electronics similar to the apparatus described herein and was used to optimize the clinical performance of the embodiment 12 of the device described herein.

TABLE 1
STAGE I TREATMENT RESULTS
RESPONSE IUDR ACYCLOVIR ® TOTALS
No response 1 1 2
Some response 1 3 4
Major response 26 42 68

The study included a control situation wherein seven patients were found who had simultaneous concurrent herpes lesions at separate locations on their bodies. In each case one lesion was treated with iontophoretic application of antiviral agent (Acyclovir® or IUDR) and the other lesion was treated in the standard method employed in the prior art comprising repeated topical application of the same antiviral agent. The iontophoretically enhanced treated lesion received a single 10-15 minute treatment. All iontophoretically treated lesions demonstrated resolution in 24 hours and none of the unassisted topically treated lesions demonstrated a similar response. The results for the control group are summarized in Table 2.

TABLE 2
CONTROL GROUP RESULTS
No response Some resp. Major resp.
IUDR
Treated lesion 0 0 7
Control lesion 5 2 0
ACYCLOVIR ®
Treated lesion 0 0 1
Control lesion 1 0 0

The clinical studies included patient volunteers with full informed consent who suffered from recurrent cold sores. The study demonstrated greatest treatment efficacy if the herpes lesion received iontophoretic treatment within 36 hours of lesion onset. The treatment incorporated an electrode saturated with Acyclovir® ointment (ZOVIRAX®) or IUDR (STOXIL®) ophthalmic drops as supplied by the manufacturer. Thus mounted Anodic electrode of the prototype system was used for a 10-15 minute application directly to the lesion with the average current setting of 0.2 ma-0.6 ma which was well tolerated by all patients.

The lesion was evaluated in 24 hours. In 92% of the iontophoretically treated cases (>70 lesions treated) a major response was noted. A major response was categorized by resolution of pain in <6 hours and lesion crusted and healing within 24 hours. The normal course of cold sores involves an average period of 10-12 days before resolution and healing occurs. The present apparatus and clinical method for treatment of mucocutaneous Herpes Simplex (type I and Type II) eruptions presented herein have been described and performed with excellent results. This novel user friendly apparatus in combination with the disclosed clinical treatment method presents a very effective new treatment for Herpes Simplex eruptions.

While the invention has been described above with references to specific embodiments thereof, it is apparent that many changes, modifications and variations in the materials, arrangements of parts and steps can be made without departing from the inventive concept disclosed herein. For example, an impregnated conductive gel can also be used to as medicament containing medium to increase the physical stability and the tissue adhering characteristics of the electrode. Accordingly, the spirit and broad scope of the appended claims is intended to embrace all such changes, modifications and variations that may occur to one of skill in the art upon a reading of the disclosure. All patent applications, patents and other publication cited herein are incorporated by reference in their entirety.

Citations de brevets
Brevet cité Date de dépôt Date de publication Déposant Titre
US27952429 janv. 188319 juin 1883 Thimble
US484522 *21 juil. 189218 oct. 1892 Edward h
US600290 *24 août 18978 mars 1898 Therapeutic electrode
US2126070 *29 avr. 19329 août 1938Charles Wappler FrederickElectrotherapy
US283434420 juil. 195513 mai 1958Lion Brush K KDevice for penetrating teeth with fluoride
US3019787 *5 oct. 19606 févr. 1962Simmons Joe JApparatus for electrolytic dental desensitization
US30481708 nov. 19607 août 1962Lemos AlbanoElectrical devices for the application of fluid to the gums
US310767218 mai 195922 oct. 1963Ewald RoseElectrical apparatus for cosmetic treatment of the skin
US316316628 avr. 196129 déc. 1964Colgate Palmolive CoIontophoresis apparatus
US329836824 avr. 196417 janv. 1967Peter CharosHeated cream applicator gloves
US3520297 *31 janv. 196714 juil. 1970Chemway CorpIontophoretic toothbrush
US364526017 juil. 197029 févr. 1972Health Systems IncDental desensitizer
US3716054 *11 août 197013 févr. 1973Porter WApparatus for applying medication to teeth and body tissue
US383159828 sept. 197227 août 1974Tice ISterile anesthetic instruments
US432536719 nov. 197920 avr. 1982Robert TapperIontophoretic treatment apparatus
US43835293 nov. 198017 mai 1983Wescor, Inc.Iontophoretic electrode device, method and gel insert
US44745708 juil. 19822 oct. 1984Kabushikikaisya Advance Kaihatsu KenkyujoTipical electroosmosis
US451093922 déc. 198216 avr. 1985Biosonics, Inc.Means for transferring electrical energy to and from living tissue
US4665921 *16 mai 198519 mai 1987Teranishi Electric Works, Ltd.High potential generating toothbrush
US4689039 *1 juil. 198625 août 1987Ken HayashibaraElectrotherapeutic apparatus for iontophoresis
US470273221 nov. 198627 oct. 1987Trustees Of Boston UniversityConveying energy to polymer matrix and active ligand
US474781929 oct. 198431 mai 1988Medtronic, Inc.Iontophoretic drug delivery
US47878881 juin 198729 nov. 1988University Of ConnecticutDisposable piezoelectric polymer bandage for percutaneous delivery of drugs and method for such percutaneous delivery (a)
US483827322 juin 198713 juin 1989Baxter International Inc.Medical electrode
US491314816 nov. 19883 avr. 1990Hepax LimitedMethod for the treatment of herpes simplex and herpes zoster
US491964820 mai 198824 avr. 1990Drug Delivery Systems Inc.High tack drug patch
US495356528 mars 19894 sept. 1990Shunro TachibanaEndermic application kits for external medicines
US49574802 févr. 198818 sept. 1990Universal Health Products, Inc.Method of facial toning
US4979938 *11 mai 198925 déc. 1990Iomed, Inc.Method of iontophoretically treating acne, furuncles and like skin disorders
US49974189 janv. 19895 mars 1991C. P. ChambersEpidermal iontophoresis device
US503738127 juil. 19906 août 1991Bock C RandolphElectrically assisted transdermal transport device and method for renewing the device
US50429757 mai 198727 août 1991Rutgers, The State University Of New JerseyIontotherapeutic device and process and iontotherapeutic unit dose
US5090402 *25 juil. 199025 févr. 1992L'orealMassaging appliance
US513335212 avr. 199028 juil. 1992Kent, Lathrop And JohnstonMethod for treating herpes simplex
US516031610 sept. 19903 nov. 1992Henley Julian LIontophoretic drug delivery apparatus
US516204227 déc. 199110 nov. 1992Alza CorporationDonor electrode electrically connected to pad of hydrophobic polymer matrix with water-soluble beneficial agent salt as microporous structure, counterelectrode electrically connected to pad with electrolyte salt, electrical power source
US5169384 *16 août 19918 déc. 1992Bosniak Stephen LApparatus for facilitating post-traumatic, post-surgical, and/or post-inflammatory healing of tissue
US520376824 juil. 199120 avr. 1993Alza CorporationTransdermal delivery device
US525002225 sept. 19905 oct. 1993Rutgers, The State University Of New JerseyIontotherapeutic devices, reservoir electrode devices therefore, process and unit dose
US527954330 avr. 199218 janv. 1994The Regents Of The University Of CaliforniaDevice for iontophoretic non-invasive sampling or delivery of substances
US528447128 juin 19908 févr. 1994Becton, Dickinson And CompanyElectrode and method used for iontophoresis
US529801729 déc. 199229 mars 1994Alza CorporationLayered electrotransport drug delivery system
US53104041 juin 199210 mai 1994Alza CorporationIontophoretic delivery device and method of hydrating same
US53123262 juin 199217 mai 1994Alza CorporationIontophoretic drug delivery apparatus
US53145022 oct. 199224 mai 1994Alza CorporationIontophoretic delivery device
US533197927 juil. 199226 juil. 1994Henley Julian LIontophoretic cigarette substitute
US53543211 oct. 199111 oct. 1994Mario BergerPatch arrangement for galvanic treatment
US53604409 mars 19921 nov. 1994Boston Scientific CorporationIn situ apparatus for generating an electrical current in a biological environment
US53623074 oct. 19918 nov. 1994The Regents Of The University Of CaliforniaMethod for the iontophoretic non-invasive-determination of the in vivo concentration level of an inorganic or organic substance
US53623085 oct. 19938 nov. 1994Rutgers, The State University Of New JerseyDisposable dosage unit for iontophoresis-facilitated transdermal delivery, related devices and processes
US53742417 avr. 199320 déc. 1994Iomed, Inc.Conductive element, reticulated element having pluarlity of reticulum laoded or applied thereto hydrophilic polymer
US53742427 déc. 199320 déc. 1994Alza CorporationIontophoretic delivery device and power supply therefor
US537610722 oct. 199227 déc. 1994Kowa Co., Ltd.Electrotherapeutic device
US539119515 avr. 199221 févr. 1995B.V. Optische Industrie De Oude DelftDevice for carrying out an iontophoresis treatment on a patient
US539531021 déc. 19907 mars 1995Alza CorporationFor use on the skin of a patient
US541359013 juil. 19929 mai 1995Innovative Medical Devices (Uk) Ltd.Skin treatment device
US541562915 sept. 199316 mai 1995Henley; Julian L.Programmable apparatus for the transdermal delivery of drugs and method
US542181614 oct. 19926 juin 1995Endodermic Medical Technologies CompanyUltrasonic transdermal drug delivery system
US54419367 déc. 199315 août 1995Houghten Pharmaceuticals, Inc.Treatment of herpes simplex
US5443441 *12 nov. 199322 août 1995De Claviere; Anne MarieApparatus and method for transdermal delivery of cosmetic compositions
US54585698 juin 199317 oct. 1995Becton Dickinson And CompanyWearable iontophoresis system
US546438727 oct. 19947 nov. 1995Alza CorporationTransdermal delivery device
US54662174 avr. 199414 nov. 1995Alza CorporationIontophoretic drug delivery apparatus
US547034916 juin 199228 nov. 1995Courage & Khazaka Electronic GmbhDevice for treating inflammatory skin changes in the initial stage, and method for using same
US549467928 déc. 199327 févr. 1996Becton Dickinson And CompanyMolecules for iontophoretic delivery
US55017059 déc. 199226 mars 1996Fakhri; OmarMethod for the treatment of psoriasis with electric current
US551416724 oct. 19947 mai 1996Mgb Technologies CorporationHand holdable human skin treatment apparatus
US55586323 nov. 199424 sept. 1996Iomed, Inc.Electrodes for iontophoresis
US556260718 janv. 19958 oct. 1996Alza CorporationElectrotransport device having reusable controller power saver
US55895631 avr. 199431 déc. 1996The Polymer Technology GroupSurface-modifying endgroups for biomedical polymers
US5603693 *6 sept. 199418 févr. 1997Asulab S.A.Three part device for the transdermic administration of drugs by electrophoresis or iontophoresis
US560746120 oct. 19954 mars 1997Nexmed, Inc.Apparatus and method for delivering electrical stimulus to tissue
US560769124 mai 19954 mars 1997Affymax Technologies N.V.Compositions and methods for enhanced drug delivery
US561827527 oct. 19958 avr. 1997Sonex International CorporationUltrasonic method and apparatus for cosmetic and dermatological applications
US56582476 juin 199519 août 1997Henley; Julian L.Ionosonic drug delivery apparatus
US5667487 *3 oct. 199416 sept. 1997Henley; Julian L.Having skin-contacting medicant layer, multichannel iontophoresis electrode and ultrasonic electrode
US56681707 mars 199616 sept. 1997Alza CorporationComposition and method enhancing transdermal electrotransport agent delivery
US56766488 mai 199614 oct. 1997The Aps Organization, LlpIontophoretic drug delivery apparatus and method for use
US5688233 *2 nov. 199518 nov. 1997Genetronics, Inc.Electronincorporation enhanced transdermal delivery of molecules
US56978968 déc. 199416 déc. 1997Alza CorporationElectrotransport delivery device
US570045724 mai 199623 déc. 1997Dixon; Gary W.Processed product for skin and hair treatment
US571176124 févr. 199527 janv. 1998Alza CorporationTransdermal
US5713846 *27 sept. 19963 févr. 1998Becton Dickinson And CompanyIontophoretic drug delivery system, including method for activating same for attachment to patient
US57223976 juin 19953 mars 1998Altea Technologies, Inc.Enhancement of transdermal monitoring applications with ultrasound and chemical enhancers
US57258178 mars 199610 mars 1998Implemed, Inc.Antibacterial
US573325515 oct. 199631 mars 1998Novartis Finance CorporationThermopile powered transdermal drug delivery device
US57557508 nov. 199626 mai 1998University Of FloridaMethod and apparatus for selectively inhibiting activity in nerve fibers
US578866615 juin 19954 août 1998Empi, Inc.Iontophoresis electrode
US579532130 sept. 199418 août 1998Becton Dickinson And CompanyIontophoretic drug delivery system, including removable controller
US579786727 sept. 199625 août 1998Becton Dickinson And CompanyIontophoretic drug delivery system, including method for activating same for attachment to patient
US583017524 juil. 19973 nov. 1998Becton Dickinson And CompanyIontophoretic drug delivery system, including disposable patch
US5840057 *27 janv. 199524 nov. 1998Aloisi; AlessandroDevice for iontophoretic physiotherapy with frozen medicament crystals
US584621729 juil. 19978 déc. 1998Iomed, Inc.Iontophoretic bioelectrode and method of using same
US58793234 juin 19979 mars 1999The Aps Organization, LlpIonophoretic transdermal delivery of a 2-hydroxyethoxy(methyl)guanine into tissues overlying mucocutaneous herpes type i and type ii infections
US588267626 mai 199516 mars 1999Alza CorporationSkin permeation enhancer compositions using acyl lactylates
US590840116 déc. 19971 juin 1999The Aps Organization, LlpDisposable medicament dispensing applicator
US591915518 janv. 19956 juil. 1999Alza CorporationElectrotransport system having flexible connector means
US593185930 sept. 19983 août 1999Burke; Robert E.Facial toning system
US593559818 juin 199710 août 1999Becton Dickinson Research CenterIontophoretic delivery of cell adhesion inhibitors
US596148219 mars 19965 oct. 1999Rutgers, The State University Of New JerseyIontotherapeutic device and process and iontotherapeutic unit dose
US596148318 juin 19975 oct. 1999Sage; Burton H.Iontophoretic delivery of cell adhesion inhibitors
US59680057 janv. 199819 oct. 1999Tu; HoshengDevices and means for treating canker sores
US596800617 déc. 199819 oct. 1999Genetronics, Inc.Method and apparatus for a combination of electroporation and iontophoresis for the delivery of drugs and genes
US59831307 juin 19959 nov. 1999Alza CorporationElectrotransport agent delivery method and apparatus
US600430918 avr. 199721 déc. 1999Alza CorporationMethod and apparatus for controlled environment electrotransport
US600454729 sept. 199721 déc. 1999Focal, Inc.Apparatus and method for local application of polymeric material to tissue
US6006130 *15 juin 199521 déc. 1999Hisamitsu Pharmaceutical Co.Iontophoresis electrode and iontophoresis device using the electrode
US601867929 janv. 199725 janv. 2000Novartis Finance Corp.Iontophoretic transdermal delivery and control of adverse side-effects
US60236391 mai 19988 févr. 2000Hakky; SaidNon-invasive bodily fluid withdrawal and monitoring system
US603207326 mars 199629 févr. 2000Novartis AgIontophoretic transdermal system for the administration of at least two substances
US603848522 avr. 199914 mars 2000Axelgaard Manufacturing Co., Ltd.Current-controlling electrode
US60412527 juin 199521 mars 2000Ichor Medical Systems Inc.Drug delivery system and method
US60412531 avr. 199621 mars 2000Massachusetts Institute Of TechnologyElectroporation, vacuum or mechanical pressure.
US6048545 *22 juil. 199611 avr. 2000Biozone Laboratories, Inc.Administering uncharged dye and anesthetic
US60573745 déc. 19972 mai 2000Alza CorporationComposition, device, and method for electrotransport agent delivery
US610141124 sept. 19988 août 2000Newsome; David A.Dilation enhancer
US6167302 *15 avr. 199726 déc. 2000Iomed, Inc.Device for transcutaneous administration of medications using iontophoresis
AT232642B Titre non disponible
EP0617979A128 mars 19945 oct. 1994Faro Juan Jose VillarManual device for carrying out an iontophoresis treatment
Citations hors brevets
Référence
1"A Method of Antibiotic Administration in the Burn Patient," Rapperport et al.; Plastic and Reconstructive Surgery, vol. 36, No. 5, pp. 547-552.
2"A Pilot Study of Iontophoretic Cisplatin Chemotherapy of Basal and Squamous Cell Carcinomas of the Skin," Chang et al., Arch. Dermatol., vol. 129, pp. 425-427, Apr. 1993.
3"Acyclovir and Vidarabine Monophosphate: Comparison of Iontophoretic and Intravenous Administration for the Treatment of HSV-1 Stromal Keratitis," Hill et al., The American Journal of Medicine, Acyclovir Symposium, pp. 300-304.
4"Anesthesia of the Human Tympanic Membrane by Iontophoresis of a Local Anesthetic," Comeau et al. The Laryngoscope, 88: 1978, pp. 277-285.
5"Antibiotic Iontophoresis in the Treatment of Ear Chondritis," LaForest et al., Physical Therapy, vol. 58, No. 1, Jan. 1978, pp. 32-34.
6"Antiherpesviral and Anticellular Effects of 1-beta-D-Arabinofuranosyl-E-5-(2-Halogenovinyl) Uracils," Machida et al., Antimicrobial Agents and Chemotherapy, Jul. 1981, pp. 47-52.
7"Azelaic Acid 20% Cream (AZELEX(R)) and the Medical Management of Acne Vulgaris," Gibson, Dermatology Nursing, vol. 9, No. 5, pp. 339-344.
8"Azelaic Acid: Potential as a General Antitumoural Agent," Breathnach, Medical Hypotheses (1999) 52(3) 221-226.
9"Common Cold" Virus is Near, Haney, The Associated Press, Jan. 15, 2000.
10"Conductivity of Drugs Used for Iontophoresis," Gangarosa et al., Journal of Pharmaceutical Sciences, vol. 67, No. 10, pp. 1439-1443, Oct. 1978.
11"Early Application of Topical 15% Idoxuridine n Dimethyl Sulfoxide Shortens the Course of Herpes Simplex Labialis: A Multicenter Placebo-Controlled Trial," Spruance et al., The Journal of Infectious Diseases, 1990; vol. 161; pp. 191-197.
12"Eczemia/Atopic Dermatitis," American Academy of Dermatology, 1987, Revised 1991, 1993, 1995.
13"Effect of Iontophoretic and Topical Application of Antiviral Agents in Treatment of Experimental HSV-1 Keratitis in Rabbits," Kwon et al., Investigative Opthalmology & Visual Science, vol. 18, No. 9, pp. 984-988, Sep. 1979.
14"Efficacy and Safety of Azelaic Acid and Glycolic Acid Combination Therapy Compared with Tretinoin Therapy for Acne," Spellman et al., Clinical Therapeutics, vol. 20, No. 4, 1998.
15"Electrophoretic Evaluation of the Mobility of Drugs Suitable for Iontophoresis," Kamath et al., Meth. Find., Exp. Clin. Pharmacol., 1995, 17(4): pp. 227-232.
16"Electrorepulsion Versus Electroosmosis: Effect of pH on the Iontophoretic Flux of 5-Fluorouracil," Merino et al., Pharmaceutical Research, vol. 16, No. 6 (1999).
17"Gelatin-stabilised Microemulsion-Based Oranogels: Rheology and Application in Iontophoretic Transdermal Drug Delivery," Kantaria et al., Journal of Controlled Release 60 (1999) 355-365.
18"Herpes Simplex," American Academy of Dermatology.
19"How Modern Iontophoresis Can Improve Your Practice," Gangarosa et al.; Oral Surgery, No. 10, Report 2135, Oct. 1982, pp. 1027-1038.
20"Infection with Herpes-Simplex Viruses 1 and 2," Nahmias et al.; The New England Journal of Medicine, pp. 667-674, Sep. 27, 1973.
21"Ionotophoresis and Herpes Labialis," Boxhall et al.; The Medical Journal of Australia, May 26, 1984, pp. 686-687.
22"Iontophoresis Enhances the Transport of Acyclovir Through Nude Mouse Skin by Electrorepulsion and Electroosmosis," Volpato et al., Pharmaceutical Research, vol. 12, No. 11, pp. 1623-1627, 1995.
23"Iontophoresis of Vidarabine Monophosphate for Herpes Orolabialis," Gangarosa et al.; The Journal of Infectious Diseases, vol. 154, No. 6, pp. 930-934, Dec. 1986.
24"Iontophoresis: Applications in Transdermal Medication Delivery," Costello et al.; Physical Therapy, vol. 75, No. 6, pp. 104/554-113/563, Jun. 1995.
25"Iontophoresis: Electrorepulsion and Electroosmosis," Guy et al., Journal of Controlled Release 64 (2000) 129-132.
26"Iontophoretic Application of Adenine Arabinoside Monophosphate for the Treatment of Herpes Simplex Virus Type 2 Skin Infections in Hairless Mice," Gangarosa, The Journal of Infectious Diseases, vol. 140, No. 6, pp. 1014, Dec. 1979.
27"Iontophoretic Application of Adenine Arabinoside Monophosphate to Herpes Simplex Virus Type 1-Infected Hairless Mouse Skin," Park et al.; Antimicrobial Agents and Chemotherapy, vol. 14, No. 4, Oct., 1978, pp. 605-608.
28"Iontophoretic Application of Antiviral Chemotherapeutic Agents," Hill et al., Annals New York Academy of Sciences, pp. 604-612.
29"Iontophoretic Application of Antiviral Drugs," Gangarosa et al., Proceedings of an International Symposium held in Tokushima City, Japan, pp. 200-204, Jul. 27-30, 1981.
30"Iontophoretic Application of Drugs," Waud, J. Appl. Physiol. 23(1), 1967, pp. 128-130.
31"Iontophoretic Application of Idoxuridine for Recurrent Herpes Labialis: Report of Preliminary Chemical Trials," Gangarosa et al.; Meth. And Find. Exptl. Clin. Pharmacol. 1(2), pp. 105-109 (1979).
32"Iontophoretic Assistance of 5-Iodo-2'-Deoxyuridine Penetration into Neonatal Mouse Skin and Effects of DNA Synthesis," Gangarosa et al., Society for Experimental Biology and Medicine, pp. 439-443, 1977.
33"Iontophoretic Treatment of Herpetic Whitlow," Gangarosa et al., Arch. Phys. Med. Rehabil., vol. 70, Apr. 1989.
34"Iontophoretic Treatment of Oral Herpes," Henley et al.; Laryngoscope, vol. 94, No. 1, pp. 118-121, Jan. 1984.
35"Iontrophoresis for Enhancing Penetration of Dermatologic and Antiviral Drugs," Gangarosa et al., Journal of Dermatology, vol. 22, No. 11, pp. 865-875, Nov. 1995.
36"Iotonphoresis for Surface Local Anesthesia,"Gangarosa, JADA, vol. 88, pp. 125-128, Jan. 1974.
37"New Medicines Move to Eradicate Acne," Hemphill, The New York Times, Feb. 29, 2000.
38"Ocular Iontophoresis," Hill et al. Paper, Louisiana State University Medical Center, School of Medicine, New Orleans, Louisiana, pp. 331-354.
39"Passive versus Electrotransport-Facilitated Transdermal Absorption of Ketorolac," Park et al.; Clinical Pharmacology & Therapeutics, vol. 63, No. 3, pp. 303-314.
40"Postherpetic Neuralgia," Baron et al.; Brain (1993), 116, pp. 1477-1496.
41"Psoriasis,"American Academy of Dermatology, 1994.
42"Skin Cancer: An Undeclared Epidemic," American Academy of Dermatology, 1988, Revised, 1989, 1993, 1994.
43"Soriudine Versus Acyclovir for Treatment of Dermatomal Herpes Zoster in Human Immunodeficiency Virus-Infected Patients: Results from a Randomized, Controlled Clinical Trial," Gnann et al., Antimicrobial Agents and Chemotherapy, vol. 42, No. 5, May 1998, pp. 1139-1145.
44"Sorivudine: A Promising Drug for the Treatment of Varicella-Zoster Virus Infection," Whitley, Neurology 1995; 45 (Supp. 8), pp. S73-S75.
45"The Natural History of Recurrent Herpes Simplex Labialis," Spruance et al.; The New England Journal of Medicine, vol. 297, No. 2, pp. 69-75, Jul. 14, 1977.
46"The Quantity and Distribution of Radiolabeled Dexamethasone Delivered to Tissue by Iontophoresis," Glass et al.; International Journal of Dermatology, vol. 19, Nov. 1980, pp. 519-525.
47"Thymine Arabinoside (Ara-T) Topical and Iontophoretic Applications for Herpes Simplex Virus Type 1 and Type 2 Skin Infections in Hairless Mice," Hill et al., Meth. And Find. Exptl. Clin. Pharmacol. 6(1), pp. 17-20, 1984.
48"Transdermal Drug Delivery by Passive Diffusion and Iontophoresis: A Review," Singh et al., Medicinal Research Reviews, vol. 13, No. 5, pp. 569-621 (1993).
49"Treatment of Common Cutaneous Herpes Simplex Virus Infections," Emmert, American Family Physician, vol. 61, No. 6, Mar. 15, 2000, pp. 1697-1704.
50"Treatment of Mucocutaneous Herpes Simplex Virus Infections Unresponsive to Acyclovir with Topical Foscarnet Cream in AIDS Patients: A Phase I/II Study," Javaly et al., Journal of Acquired Immune Deficiency Syndromes 21:301-306.
51"Warts," American Academy of Dermatology, American Academy of Dermatology, 1997, Revised 1991, 1993.
52"Antiherpesviral and Anticellular Effects of 1-β-D-Arabinofuranosyl-E-5-(2-Halogenovinyl) Uracils," Machida et al., Antimicrobial Agents and Chemotherapy, Jul. 1981, pp. 47-52.
53"Azelaic Acid 20% Cream (AZELEX®) and the Medical Management of Acne Vulgaris," Gibson, Dermatology Nursing, vol. 9, No. 5, pp. 339-344.
54"Iontophoretic Assistance of 5-Iodo-2′-Deoxyuridine Penetration into Neonatal Mouse Skin and Effects of DNA Synthesis," Gangarosa et al., Society for Experimental Biology and Medicine, pp. 439-443, 1977.
55Physical Enhancement of Dermatologic Drug Delivery: Iontophoresis and Phonophoresis: Kassan et al.; Journal of the American Academy of Dermatology, Apr. 1996, pp. 657-666.
Référencé par
Brevet citant Date de dépôt Date de publication Déposant Titre
US6735470 *18 sept. 200211 mai 2004Biophoretic Therapeutic Systems, LlcElectrokinetic delivery of medicaments
US77068735 mai 200427 avr. 2010Mario AmmiratiSystem and method for controlled delivery of a therapeutic agent to a target location within an internal body tissue
US8352024 *13 mars 20068 janv. 2013Nitric Biotherapeutics, Inc.Electrokinetic delivery system for self-administration of medicaments and methods therefor
US86664863 mars 20054 mars 2014Hadasit Medical Research Services & Development LimitedSafe device for iontophoretic delivery of drugs
WO2005084748A1 *3 mars 200515 sept. 2005Hadasit Med Res ServiceSafe device for iontophoretic delivery of drugs
Classifications
Classification aux États-Unis604/20, 604/289, 604/501
Classification internationaleA61N1/30
Classification coopérativeA61N1/30
Classification européenneA61N1/30
Événements juridiques
DateCodeÉvénementDescription
8 avr. 2011ASAssignment
Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:GENERAL ELECTRIC CAPITAL CORPORATION;REEL/FRAME:026097/0089
Effective date: 20110404
Owner name: NITRIC BIOTHERAPEUTICS, INC., PENNSYLVANIA
9 sept. 2010FPAYFee payment
Year of fee payment: 12
3 nov. 2009ASAssignment
Owner name: GENERAL ELECTRIC CAPITAL CORPORATION, ILLINOIS
Free format text: ASSIGNMENT OF SECURITY INTEREST IN INTELLECTUAL PROPERTY;ASSIGNOR:TRANSPORT PHARMACEUTICALS, INC.;REEL/FRAME:023456/0493
Owner name: NITRIC BIOTHERAPEUTICS, INC., PENNSYLVANIA
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:TRANSPORT PHARMACEUTICALS, INC.;REEL/FRAME:023456/0269
Effective date: 20091030
Owner name: TRANSPORT PHARMACEUTICALS, INC., MASSACHUSETTS
Free format text: TERMINATION AND RELEASE OF SECURITY INTEREST RECORDED AT REEL 022529, FRAME 0922;ASSIGNOR:GENERAL ELECTRIC CAPITAL CORPORATION;REEL/FRAME:023456/0389
Free format text: SECURITY AGREEMENT;ASSIGNOR:NITRIC BIOTHERAPEUTICS, INC.;REEL/FRAME:023456/0433
14 avr. 2009ASAssignment
Owner name: GENERAL ELECTRIC CAPITAL CORPORATION, CONNECTICUT
Free format text: SECURITY AGREEMENT;ASSIGNOR:TRANSPORT PHARMACEUTICALS, INC.;REEL/FRAME:022529/0922
Effective date: 20090410
14 août 2006FPAYFee payment
Year of fee payment: 8
5 oct. 2005ASAssignment
Owner name: TRANSPORT PHARMACEUTICALS, INC., PENNSYLVANIA
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BIOPHORETIC THERAPEUTIC SYSTEMS, LLC;REEL/FRAME:016621/0042
Effective date: 20050929